HOME  |  CONTACT  
  spi2012  
 
sachs associates   Sachs Cancer Bio Partnering Forum
Promoting Public & Private Sector
Collaboration & Investment in Drug Development
    21st – 22nd May 2013 • Westin Copley Place, Boston
 
  spi2012  
 
 
Register Now
 
Register
To Exhibit
 
Register
To Present
 
sachs sachs sachs sachs sachs sachs sachs
Biotech i Europe Investor Forum
 
sachs sachs
 
Keynote Speeches by:
Dr Susan Love Dr Susan Love
View Profile >
Prof Edward Benz Prof. Edward Benz
View Profile >
Lynda Chin Lynda Chin
View Profile >
Alykhan Shamji Alykhan Shamji
View Profile >
Dr Bruce Crise Dr Bruce Crise
View Profile >
 
Confirmed Presenting
Companies Include:

Aileron Therapeutics, Inc.
AnaptysBio, Inc
Argos Therpeutics, Inc
Atossa Genetics
BioCancell Ltd.
BioLineRx Ltd.
Cellectis
CENTROSE
Churchill Pharmaceuticals
Constellation Pharmaceuticals
CureVac GmbH
Dicerna Pharmaceuticals
Etubics Corporation
Genisphere
immatics biotechnologies GmbH
ImmunoGen, Inc
Life Science Nation
MacroGenics, Inc
Melanovus Oncology
MiNA Therapeutics
MolecularMD
Oncolix, Inc.
OncoSec Medical Incorporated
Oxford BioTherapeutics
RAMOT at Tel Aviv University
Rescue Therapeutics, Inc.
Sialix, Inc.
Sorrento Therapeutics
to-BBB technologies BV
TVAX Biomedical, Inc.
More TBA...

 

 

For Keynote Speakers profiles please click on name.

Conference will feature Keynote Speeches made by:

Dr Susan Love, President, Dr Susan Love Research Foundation

Susan Love

Susan Love MD, MBA has dedicated her professional life to the eradication of breast cancer. As President of the Dr. Susan Love Research Foundation, she oversees an active research program centered on breast cancer cause and prevention. She is also a Clinical Professor of Surgery at UCLA’s David Geffen School of Medicine.

Dr. Love received her medical degree from SUNY Downstate Medical Center in New York and did her surgical training at Boston’s Beth Israel Hospital. She founded the Faulkner Breast Center in Boston and the Revlon UCLA Breast Center in Los Angeles. She has a business degree from the Executive MBA program at UCLA’s Anderson School. In 1996 she retired from the active practice of surgery, to dedicate her time to the urgent pursuit of finding the cause and prevention of breast cancer. She has done this in the for-profit and the non-profit arena, including creating several medical device companies based on the intraductal approach to the breast.

Her reputation as an activist comes from her role as one of the “founding mothers” of the breast cancer advocacy movement in the early 1990’s. She was one of the founders of the National Breast Cancer Coalition (NBCC). She served on the National Cancer Advisory Board from 1998-2004 as an appointment of President Clinton.

Dr. Susan Love is best known as a trusted guide to women worldwide through her books and the Foundation website. The completely revised fifth edition of Dr. Susan Love’s Breast Book termed “the bible for women with breast cancer” by The New York Times was released October 2010. It has been translated into German, Dutch, Chinese, Japanese and Hebrew. Dr. Susan Love’s Menopause and Hormone Book, first published in 1998 and revised in 2003, was one of the first to sound the alarm against the long term use of postmenopausal hormones. Live a Little (Crown 2009) encourages women to take a reasonable approach to becoming healthy.

A true visionary, Susan Love’s recent projects include the Love/Avon Army of Women (through the Dr. Susan Love Research Foundation), a creative Internet solution to partner women and scientists to accelerate basic translational research. The campaign is recruiting one million women who are willing to consider participating in research to find the cause and prevention of breast cancer. This novel initiative will move research from animals to women, democratizing the scientific process. To date, over 370,000 women and men have signed up to participate. In October 2012, the Dr. Susan Love Research Foundation launched the Health of Women Study (HOW), a first of its kind, global, online cohort study focused on identifying new risk factors for breast cancer.

Professor Edward Benz, Richard and Susan Smith Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Harvard Medical School,
President, Dana-Farber Cancer Institute

Professor Edward Benz

The Critcal Role of Collaboration and Team Science in Bridging the Translational Divide

Professor Edward J. Benz, Jr is President and CEO of the Dana-Farber Cancer Institute and the Richard and Susan Smith Professor of Medicine, professor of pediatrics, and professor of pathology at Harvard Medical School. Dr. Benz was elected to The Rockefeller University Board of Trustees in 2004.An internationally recognized hematologist, he is an expert in inherited anemias and diseases of the red cell. His laboratory studies, which are funded by the National Institutes of Health, focus on the molecular regulation and functions of membrane cytoskeletal proteins that were originally discovered in the red blood cell.

Dr. Benz is also CEO of Dana-Farber/Partners CancerCare, Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center, Director of Dana-Farber/Brigham and Women’s Cancer Center, and a member of the Governing Board of Dana-Farber/Children’s Hospital Cancer Center.

Dr. Benz graduated from Harvard Medical School and received his training at Brigham and Women’s Hospital. He later served as Chair of the Departments of Medicine at the University of Pittsburgh and then at Johns Hopkins, where he held the prestigious Sir William Osler Professorship of Medicine. He currently serves as Past President of the Friends of the National Institute of Nursing Reseaerch, and has been elected President of the American Association of Cancer Institutes.

Dr. Benz’s many honors include membership in the Institute of Medicine of the National Academy of Sciences and the American Association of Arts and Sciences. He has served on numerous NIH committees and currently chairs the NIH Advisory Board for Clinical Research. He is a past president of both the American Society of Hematology and the American Society of Clinical Investigation. Dr. Benz is married to Dr. Margaret Vettese, a nurse scientist and educator. They have four children.

Lynda Chin, MD, Professor, Chair, Dept of Genomic Medicine, Scientific Director, Institute for Applied Cancer Science, M.G. & Lillie A. Johnson Chair for Cancer Treatment and Research, UT MD Anderson Cancer Center

Lynda Chin

Lynda Chin, M.D. trained as a physician at Albert Einstein College of Medicine in 1993, and is a board-certified dermatologist. She conducted her clinical and scientific training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine where she was appointed Chief Resident of Dermatology. Previous to joining the University of Texas MD Anderson Cancer Center in 2011, she was a member of the Dana-Farber Cancer Institute and Harvard Medical School communities. Chin was one of the founding faculty members and the Scientific Director of the Belfer Institute for Applied Cancer Science.

Chin is the founding chair of the Department of Genomic Medicine at MD Anderson. She also serves as the scientific director of the Institute for Applied Cancer Science, which merges the best attributes of academia and industry to enable science-driven drug discovery. Chin is a leader in translational genomic medicine and her research program spans the fields of transcription, telomere biology, mouse models of human cancer, cancer genomics, and personalized cancer medicine. She is also at the forefront of comparative oncogenomics of mouse and human cancers and its integration with functional genomics to identify novel cancer genes and therapeutic targets.

Chin is also actively involved in The Cancer Genome Atlas, where she holds multiple leadership roles. She is also a member of the Scientific Steering Committee of the International Cancer Genome Consortium. Chin was elected a member of the Institute of Medicine in 2012. She co-founded AVEO Pharmaceuticals in 2002, which emphasizes cancer biology and genetics to identify new cancer targets with tumor maintenance roles. More recently, Chin also founded Metamark Genetics, a diagnostic company that develops function-based prognostic determinants to guide the customized management of early-stage cancer patients with melanoma or prostate cancer. Chin has three young children, ages 11, 10 and 8.

Alykhan Shamji, Associate Director, Chemical Biology Program,
Broad Institute of Harvard and MIT

Alykhan Shamji

Alykhan Shamji joined the Broad Institute as the Associate Director of the Chemical Biology Program in 2007. He works closely with Broad investigators interested in applying chemical biology approaches to advance the mission of the institute: accelerating the understanding and treatment of disease. He leads a research group in this area, and oversees the financial and operational administration of the program.

His work focuses on the discovery and characterization of small molecules with potential to impact disease research and medicine. Working with the scientific community, his group aims to understand the relationship between disease genetics, pathophysiology, and the response to small molecules, with the goal of defining and testing strategies for therapeutic intervention. His projects focus on cancer, diabetes, and inflammatory bowel disease.

Before joining the Broad, Shamji was a management consultant at the Boston Consulting Group, focusing on pharmaceuticals, clinical diagnostics, and strategic acquisitions. He received both his A.B. in biochemical sciences and his Ph.D. in biophysics from Harvard University.

Dr Bruce Crise, Director of Business Development, Frederick National Laboratories

Dr Bruce Crise

Dr Bruce Crise serves as Director, Business Development for Scientific and Technical Operations in the Partnerships Development Office at the Frederick National Laboratory for Cancer Research (FNLCR), SAIC-Frederick since 2008. In this capacity, he leads the business development activities and serves as a scientific and technical liaison in the assessment of R&D partnerships. He plays a key role in enabling the life sciences mission of FNLCR through partnership development, advancing strategic alignment between SAIC-Frederick and NCI on opportunities for collaborations related to cancer and AIDS research. Dr. Crise joined SAIC-Frederick in 2000, and prior to his current role, he held scientific management positions as director of the Gene Expression Laboratory and as the senior scientist in the Retroviral Vaccine Laboratory. Prior to 2000, he conducted research at the U.S. Army Medical Research Institute of Infectious Diseases, developing medical countermeasures to biological weapons. Dr. Crise earned his Ph.D. from Yale University, where he studied molecular aspects of HIV infections, and conducted his post-doctoral fellowship at the Salk Institute. He has extensive R&D experience in the field of molecular virology, vaccine development, cell biology and genetics.

Confirmed Speakers & Chairs include:

Aaron Reames, Senior Equity Analyst, Columbia Management

Aaron Reames

Aaron Reames is a senior equity analyst for Columbia Management Investment Advisors, LLC (CMIA). Mr. Reames is responsible for equity research and coverage of the biotechnology and emerging specialty pharmaceutical sectors. He joined the firm in 2010 and has been a member of the investment community since 1998.

Prior to joining Columbia, Mr Reames worked as a senior analyst at Wells Fargo Securities (formerly Wachovia) where he was a Director, Equity Research and Senior Analyst covering the biotechnology sector. He covers a broad range biotechnology companies focused on developments in the areas of oncology, antiretrovirals, cardiology, metabolic disorders and CNS. Reames joined Wells from AG Edwards where he was a Vice-President covering the same space.

Before beginning his career as a sell-side analyst, Mr. Reames was director of the Biotechnology Group for JPS Capital, where he led licensing deals, M&A transactions and partnerships. He was also a performance measurement and investment analyst at Banc One Investment Advisors, the investment arm for Bank One Corporation (now JPMorgan Chase & Co.). In addition, he has served as an adjunct professor of finance at Columbus State University in Columbus, OH.

Mr. Reames brings 11 years of biotechnology and molecular genetics laboratory experience in the fields of entomology, microbiology, molecular genetics and muscle physiology. He research was conducted at the labs of The Ohio State University and Case Western Reserve University, with internships at Lawrence Berkley. Mr. Reames has received accolades for research he conducted in the filed of molecular genetics from former President of the United States George Bush Sr. and the Governor of Ohio. He has also received commendations from the U.S. Navy, Army and Marine Corp for excellence in research and has been recognized by the American Academy for the Advancement of Science, National Academy of Science, National Association of Biology Teachers, American Society for Microbiology and NASA.

Mr. Reames received his B.S. in biology from Ohio State University and his M.B.A from Franklin University in Columbus, Ohio.

Anne Altmeyer, Vice President, Business Development & Licensing, Novartis

Anne Altmeyer

Anne Altmeyer is a Vice President in Business Development and Licensing in the Oncology Business Unit at Novartis, USA. Her responsibilities are to in-license or acquire Oncology assets that can further strengthen the Novartis Oncology portfolio. In this role, she identifies, evaluates, and negotiates transactions for oncology opportunities. She also manages several ongoing alliances.

Anne has over 15 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in Research, Development, and Business Development and Licensing. Anne joined the Oncology Project Management group of Novartis in 2004 as a Project Leader. There she led numerous multidisciplinary Project Teams through the generation and implementation of strategies for various compounds in development and on the market. Before joining Novartis, Anne worked as a Project Manager in various Therapeutic Areas at Merck & Co. for about 4 years and as a Visiting Research Scientist for 2 years.

Anne received her Ph.D. in Molecular Immunology from Strasbourg University, France. She then performed a postdoctoral fellowship at New York University School of Medicine, USA, and subsequently became a Research Associate at Cornell University Medical College, New York, USA. In addition to her scientific training, Anne also received a Master in Business Administration and a Master in Public Health from the University of Medicine and Dentistry of New Jersey/Rutgers, USA.

Ansbert Gadicke, Managing Director, MPM Capital

Ansbert Gadicke

Dr Ansbert Gadicke is a Co-Founder and Managing Director of MPM Capital. He led MPM's effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996.

Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt. He held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT and the Biochemistry Department at Harvard University. At the German Cancer Research Center, Dr. Gadicke cloned the first cDNAs of HPV16 and 18 in Prof. Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Dr. Gadicke has published in leading scientific publications including Nature and Cell.

He is a member of the Board of Fellows of Harvard Medical School and the MGH Research Advisory Council.

Past Boards: BioMarin Pharmaceuticals, Inc. (NASDAQ:BMRN) • Biovitrum AB (Stockholm:BVT) • Chiasma, Inc. •Coelacanth Corp. • Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) •Kourion Therapeutics AG (acquired by VIAC) •MediGene AG (Frankfurt:MDG) • Omrix (NASDAQ:OMRI) (acquired by JNJ) • National Venture Capital Association • Pharmasset, Inc. (NASDAQ:VRUS) (acquired by GILD) • PharmAthene (PIP) • Solasia Pharma K.K., Tokyo • Transform (acquired by JNJ) • Verastem, Inc. (NASDAQ:VSTM) • ViaCell (NASDAQ:VIAC) (acquired by PKI).

Armen Shanafelt, Venture Partner, Lilly Ventures

Armen Shanafelt

Dr Shanafelt is a Venture Partner at Lilly Ventures, and has over 22 years of experience in the pharmaceutical, biotechnology and diagnostic businesses. Prior to joining Lilly Ventures, he was CSO responsible for the generation of the biotherapeutic pipeline for Lilly, including the therapeutic areas of oncology, endocrine, neuroscience, and autoimmunity. He currently serves as a director on the boards of HemaQuest Pharmaceuticals, Protagonist Therapeutics, and Sutro Biopharma, and is a Kauffman Fellow (Class 14).

Aya Jakobovits, Venture Partner, Orbimed Israel and CEO, Kite Pharma

Aya Jakobovits

Dr Jakobovits serves as President & Chief Executive Officer of Kite Pharma, Inc. and as a Venture Partner with Orbimed Israel Partners. Kite, her fourth biotech start-up, is developing immunotherapies that restore the patient’s immune system to fight cancer. Prior to joining Kite, Dr. Jakobovits served as Executive Vice President, Head of Research and Development at Agensys, Inc., an affiliate of Astellas Pharmaceuticals, Inc., which acquired Agensys in a deal valued at $537 million in December 2007. Prior to the acquisition, Dr. Jakobovits served as Senior Vice President, Technology and Corporate Development, and Chief Scientific Officer of Agensys, which she joined in 1999 and led its transition from a small gene discovery lab into a fully integrated biotech company. Under her leadership, the company established a large proprietary portfolio of novel cancer targets protected by a strong patent estate, a clinical pipeline of therapeutic human antibodies in multiple cancer indications, and partnerships with Genentech, Merck, Sanofi-aventis and Seattle Genetics.

Before joining Agensys, Dr. Jakobovits served as the Director, Discovery Research and Principal Scientist at Abgenix, Inc, which was spun out of Cell Genesys in 1996, based on XenoMouse® technology developed under her leadership. Abgenix was acquired by Amgen, Inc. for $2.2 billion. Dr. Jakobovits initiated the development of XenoMouse® technology in 1989 at Cell Genesys, Inc., where she was a scientist founder and served as Director of Molecular Immunology. Dr. Jakobovits was a postdoctoral fellow at Genentech, Inc. and at the University of California, San Francisco. She received her Ph.D. in Life Sciences from the Weizmann Institute of Science in Rehovot, Israel. Dr. Jakobovits is an author of over 50 scientific publications and inventor on over 100 patents related to XenoMouse® technology, proteomics technology, novel cancer targets and antibody therapeutics.

Beth Jacobs, Managing Director, Excellentia Global Partners

Beth Jacobs

Beth Jacobs currently serves as Managing Partner of Excellentia Global Partners, a global life sciences investment bank, founded in 2008. Most recently, Beth was a General Partner at Bio-IB, a lifesciences-focused investment bank in New York.

Beth has served in senior executive roles in her twenty five years of experience in both investment banking and in the corporate sector. Prior to 2003, Beth was Managing Director and Co-Head of Global Capital Markets at ING Barings, shortly after their acquisition of Furman Selz LLC, where she founded and led its international institutional equity group for over 7 years. She started her career at Prudential Securities where she founded the international institutional equity business, and later headed the same product execution group at both Morgan Stanley and Lehman Brothers.

She currently serves on the Board of Directors of EF Foundation, a global educational services company based in Stockholm and Cambridge, Mass, Board of Governors of the New York Academy of Sciences, founding Global Ambassador for Susan G. Komen for the Cure, Board member for both the Harvard Kennedy School of Government Women’s Leadership Board and the Women’s Forum of New York, and as Vice Chairman of the Board for the Budapest Festival Orchestra.

Beth received an MBA in international finance from American University in Washington, DC in conjunction with the School of Foreign Service, and a BA, cum laude, from Boston College. She also studied at Centre d’Etudes Internationale in Geneva, Switzerland.

Dan Snyder, PRESIDENT and COO, MolecularMD

Dan Snyder

Dan Snyder has more than 15 years of experience in the life science research and diagnostic fields supporting the market development of high value products and services to both pharmaceutical and academia clients. Mr. Snyder has worked extensively in supporting new product introductions and rapid market adoption for novel proteomic and genomic technologies. His commitment to customer satisfaction and close interaction with MolecularMD’s assay development laboratory helps to ensure MolecularMD meets or surpasses all client expectations.

Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance

Darryl Mitteldorf

Darryl Mitteldorf, LCSW, is an oncology social worker. Mr. Mitteldorf is the founder and Executive Director of America’s largest men’s cancer survivor support and advocacy nonprofit organization, Malecare. In 2011, working through Malecare in collaboration with several international NGO’s, Mr. Mitteldorf founded the Global Prostate Cancer Alliance. Mr. Mitteldorf is widely published, has spoken at numerous professional conferences and sits on the Board of Directors and Board of Advisors of several cancer focused nonprofit organizations, including the National LGBT Cancer Project-Out With Cancer, The New York State Prostate Cancer Coalition and the Education Network to Advance Clinical Trials. Mr. Mitteldorf holds two Masters degrees from New York University and a BA from Swarthmore College.

David Malek, VP, Business Development, BioLineRx Ltd

David Malek

David Malek, David Malek was appointed as Vice President of Business Development in October 2011. Prior to joining BioLineRx, since 2006, Mr. Malek served at Sanofi in a number of management positions in the US and France, including Marketing, Finance and Business Development. Most recently Mr. Malek served as Director of Oncology - New Products and Business Development.

Mr. Malek has an MBA from the Tuck Business School at Dartmouth College and also holds a BA in Statistics and Political Science from the University of Haifa.

Dennis Purcell, Senior Managing Director, Aisling Capital

Dennis Purcell

Dennis J. Purcell has served as the Senior Managing Director of Aisling Capital since February 2000 and is responsible for the management of the Partnership. The fund has approximately $1.7 Billion of assets under management.

Prior to joining Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at Hambrecht & Quist, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries.

During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP and honored as one of the top 50 Irish- American businessmen and cited as the top 100 contributors to the biotechnology industry. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell currently serves as a director of Paratek Pharmaceuticals, Inc., and Xanodyne Pharmaceuticals, Inc. Previously he served as a director of Aton Pharmaceuticals, Inc., Bridge Pharmaceuticals, Inc., Cengent Therapeutics, Inc., Dynova Laboratories, Inc., and Valentis, Inc.

He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association and the Irvington Institute. He also serves on the Board of L.E.K. consulting.

Mr. Purcell received his M.B.A. from Harvard University, and his B.S. in Accounting from the University of Delaware.

Doug Cole, General Partner, Flagship Ventures

Doug Cole

Doug Cole joined Flagship in 2001 where he focuses on Life Science investments. Dr. Cole holds an AB magna cum laude with High Distinction in English from Dartmouth College, and an MD from the University of Pennsylvania School of Medicine. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, MD and in neurology at the Massachusetts General Hospital in Boston, MA. In 1992, Dr. Cole was appointed Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at the Massachusetts General Hospital. He established a research program investigating the mechanistic basis of neuronal signaling events and plasticity in neuro-psychiatric disorders with the support of the NIH and several non-profit research foundations. In 1996, Dr. Cole joined Cytotherapeutics, in Providence, RI. As Medical Director, he oversaw various research and clinical activities related to the company’s cell-based therapeutic technologies. In 1997, he was appointed Program Executive at Vertex Pharmaceuticals, Inc. where he led a multidisciplinary program that conducted preclinical development through Phase II studies in tissue protection and repair, oversaw an international research collaboration, and was responsible for identifying strategic market and technology opportunities in multiple arenas. At Flagship, Dr. Cole has led investments in CombinatoRx, Tetraphase Pharmaceuticals, Alvine Pharmaceuticals, Concert Pharmaceuticals, Quanterix Corporation, Receptos, Agios Pharmaceuticals, Seventh Sense Biosystems, and Avedro. He is a co-founder of Flagship portfolio companies Ensemble Therapeutics, Permeon Biologics, ModeRNA Therapeutics, and Syros Pharmaceuticals. He currently serves on the Board of Directors of Tetraphase Pharmaceuticals, Concert Pharmaceuticals, Quanterix Corporation, Receptos, Agios, Selecta Biosciences, Avedro, and Syros.

Doug Plessinger, VP of Clinical and Medical Affairs, Argos Therapeutics

Doug Plessinger

Doug Plessinger joined Argos Therapeutics in 2011 after serving as a clinical consultant for the company for the previous 4 years. Prior to joining Argos, Mr. Plessinger was an original founder and served as the Executive Vice President and Managing Director for Axcelo MSL Solutions, a Medical Affairs and MSL consulting company. Prior to this, he served as Senior Vice President of Client Services at The Navicor Group and in other roles with Navicor and affiliated inVentiv Health companies from 2003 to 2007. Mr. Plessinger also served as a lead Medical Science Liaison (MSL) for Millennium Pharmaceuticals and held various roles of increasing responsibility for Bristol-Myers Squibb in Oncology Medical Affairs and Oncology Global Marketing from 1997 - 2003. Overall, he has more than 20 years of clinical pharmacy, pharmaceutical, and client-services related experience, including the development and launch of multiple oncology products across various solid and hematologic malignancies. Mr. Plessinger holds a B.S. degree in Pharmacy and graduated summa cum laude from Northeastern University.

Douglas Fambrough, CEO, Dicerna Pharmaceuticals

Douglas Fambrough

Douglas Fambrough is CEO of Dicerna Pharmaceuticals, a second generation RNA Interference company which he co-founded in 2007, based on breakthrough “Dicer Substrate” technology that optimizes activity and facilitates drug delivery. Prior to taking the CEO role at Dicerna, Doug was a General Partner with the Boston-based life science venture capital firm Oxford Bioscience Partners. During his 10+ years at Oxford, Doug specialized in financing innovative life science technology companies, such as first generation RNA Interference pioneer Sirna Therapeutics, acquired by Merck for $1.1 billion; Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, acquired by Illumina for $600 million; and Cambrios Technologies, which invented and now markets biologically-inspired electronic materials for touch screens and flat panel displays. Before joining Oxford, Doug was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute). He graduated from Cornell University and obtained his Ph.D. in Genetics at the University of California, Berkeley.

Eric Risser, Vice President, Business Development, MacroGenics, Inc.

Eric Risser

Eric Risser Eric Risser has over 15 years of strategy and transaction experience across both small biotechnology and large pharmaceutical companies. During his career, he has led multiple major transactions in the pharmaceuticals area, including company acquisitions, divestments, equity financings, product licenses and research collaborations. He currently leads the business development activities at MacroGenics, and was responsible for the execution of MacroGenics’ existing partnerships with Gilead, Servier, Pfizer, Boehringer Ingelheim, and Green Cross. Prior to joining MacroGenics, he served as Executive Director, Business Development at Johnson & Johnson Pharmaceuticals, which he joined in 2003. Before Johnson & Johnson, Mr. Risser started and built a successful consulting practice that provided counsel to emerging life science companies in the United States and Europe. He has also worked as a venture capitalist with BankAmerica Ventures and as an investment banker with Lehman Brothers, where he began his career in their New York and London offices. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.

Esteban Pombo Villar, Chief Operations Officer, Oxford BioTherapeutics AG

Esteban Pombo Villar

Esteban Pombo Villar is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry.

Florian Schödel, CEO, Phillimmune LLC

Florian Schoedel

Florian Schödel is the founder of Philimmune LLC, a consulting firm which provides strategic advice in the development of biologics, vaccines and pharmaceuticals. Florian has > 20 years of successful experience in leading teams in the development of vaccines and biologics in the pharmaceutical and biotech industry and in academia.

His passion is preventative medicine and the use of modern science and technology for the improvement of public health – especially in the development of preventative and therapeutic vaccines and biologics.

Florian has a track record in running scientific and operational organizations, in business and strategic planning, for forming international strategic partnerships and alliances, in target identification and in all steps of clinical and pre-clinical development.

He has directed the design and execution of clinical studies for licensure and routinely interacts with international and national regulatory agencies.

Florian has led the clinical teams responsible for several successful vaccine filings.

A physician and microbiologist by training, Florian was a VP in Vaccines Clinical Research of Merck Research Laboratories before he founded Philimmune.

Florian graduated in medicine at the Technical University, Munich, and earned doctorates in Transplantation Immunology and Medical Microbiology (Dr. med. Dr. med. habil.) from the University of Munich (LMU). He holds adjunct faculty appointments at the LMU and at the Biodesign Center of the ASU. Florian’s research at the Max-Planck Institute for Biochemistry, at Scripps, WRAIR and INSERM focused on hepatitis B and on novel recombinant vaccines against diseases such as hepB, malaria and typhoid.

Florian joined Merck Research Laboratories in 1996 as Director Clinical Vaccine Research leading EU vaccine clinical trials and the clinical development of rotavirus vaccines and varicella, measles, mumps, rubella combination and shingles vaccines. As the clinical liaison to an EU joint venture (SP-MSD) he participated in the development of pediatric combination vaccines.

Frank Jones, President, CEO, CSO, Etubics Corporation

Frank Jones

Dr Jones is a founder of Etubics Corporation and is the Company’s Chairman, Chief Executive Officer and Chief Scientific Officer. Dr. Jones has raised over $16 million for Etubics through venture capital and non-dilutive National Institutes of Health grants and contracts. He has brought the Company through the pre-clinical phase and the FDA evaluation and approval process to initiate CEA clinical trials at Duke University Medical Center.

From 1981 to 1996, Dr. Jones was a Founder and served as Chairman and Chief Executive Officer of IMRÉ Corporation, a publicly traded company. He raised over $100 million via private placements, corporate alliances, and three public offerings at IMRÉ. He also directed the Company through the start-up phase, technology development, pre-clinical studies, GMP production of its own product, preparation of patent applications for product and treatment protection, clinical trials, preparation and submission of investigational device exemptions (IDE's), submission of pre-marketing approval application data (PMA), and submission of post market approval data and documents to the FDA. Dr. Jones did the basic research for the Company’s products, wrote the treatment protocols for the human clinical trials and recruited clinical sites to test products. His area of medical and product focus is targeted at cancers and infectious diseases- with a goal of development of an armamentarium necessary to modulate and control the human immune system. Dr. Jones built strong, internationally recognized management and scientific teams to lead the Company into the production and marketing phases of corporate development; negotiated strategic alliances for clinical research and marketing of corporate products around the world and within the United States. He was the standard bearer for IMRÉ Corporation in the investment banking and finance arena as well as the scientific world.

From 1983 to 1986, Dr. Jones was Chairman of the Immune Response Program of the Pacific Northwest Research Foundation in Seattle. Dr. Jones was a Researcher in the Department of Complement and Effector Biology at Memorial Sloan Kettering Cancer Center (“MSKCC”) in New York City from 1980 to 1981 and was a Associate in the Laboratory of Veterinary Oncology at MSKCC from 1981 to 1983.

Dr. Jones holds a PhD degree from the University of Washington in Biological Structure/Cellular Immunology. He has 11 issued patents to his name, has published over 45 scientific papers, and given many business and scientific presentations on an international basis.

Guillaume Vignon, Director Business Development Oncology, Global Business Development and Licensing, Merck Serono S.A.

Guillaume Vignon

Guillaume Vignon is Director of Business Development Oncology with Merck Serono, responsible for designing deal structures and negotiating the terms of complex strategic transactions in the field of Oncology. Prior to this position, Guillaume was Director of Strategic Transactions, focusing on pre-clinical stage assets, enabling technology, antibody platforms, and companion diagnostics. During his career at Merck Serono, Guillaume closed successfully several key partnerships for Merck Serono in the field of Oncology, Companion Diagnostic, and Antibody Discovery.

Before his positions as global transactor, Guillaume served as inhouse consultant for Merck KGaA, Damstadt, Germany, leading several assignments in the field of management strategy, implementation, commercial operations BU Oncology, and business planning BU Oncology.

Guillaume holds an MBA from Hult International Business School, Cambridge, USA, and a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Pasteur Institute, Paris, France.

Hamza Suria, President & CEO,, AnaptysBio

Hamza Suria

Hamza Suria joined AnaptysBio in December 2008 and has been CEO since 2011. Prior to AnaptysBio, Mr. Suria was at Maxygen, where he was responsible for partnering and alliance management of next-generation protein therapeutics with Roche, Sanofi-Aventis, Bayer, Astellas and others. Before Maxygen, Mr. Suria was responsible for business development at Diabetogen Biosciences and Viron Therapeutics. Suria holds a B.Sc. in biochemistry from Kalamazoo College, an M.S. in immunology from the University of Western Ontario and an Executive MBA from the Richard Ivey School of Business.

Harry Glorikian, Managing Partner,, Scientia Partners

Harry Glorikian

Harry Glorikian heads Scientia Advisors with 20 years of experience in the health care and life science industries. He is known worldwide as a leader in helping companies streamline their operations and accelerate their growth.

Having held senior management positions at Applied Bio Systems, Signet Laboratories, in Massachusetts, and at X-Cell Laboratories, Inc., in California, Harry has deep commercial background in diagnostics, molecular biology, proteomics, cellular biology and biodefense. His unique understanding of technologies, operations and strategy from both customer and industry player perspectives has shaped Scientia's sophisticated framework and proprietary analytic tools.

A sought-after speaker, Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted by Dow Jones, the Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine and many other media outlets.

Harry holds an MBA from Boston University and a BA in Biology from San Francisco State University. He serves on many advisory boards and is an avid inventor who has several patents and patents pending in the US and abroad.

Henry McCusker, Director, Scimitar Equity Research

Henry McCusker

Founder and Director of Research, Henry McCusker enters his twelfth (12) year at Scimitar Equity, LLC. Past experience in sell-side analysis, buy-side management and due diligence provide keen insight and define a unique ability as a research provider.

He was VP - Strategic Planning and Communication at Curis, Inc. (2001-2002) where he was responsible for the first restructuring and the second realignment. Henry worked with Hambrecht and Quist Capital Management (HQCM) focusing on healthcare investments (NYSE:HQH/HQL) from 1985 through 2001. He also founded LifeScience Economics, a healthcare research and analytics firm with offices in Boston, MA and Palo Alto, CA.

Past experiences include manager/director at Thermo Electron, and Stone and Webster following five years at the Federal Bureau of Investigation. A former military officer, Henry has been an adjunct professor at Boston University and Golden Gate University where he taught courses in venture capital, corporate finance and strategic development in the universities' graduate business schools.

Ingmar Hoerr, CEO, CureVac

Ingmar Hoerr

Ingmar Hoerr founded CureVac with colleagues Florian von der Muelbe and Steve Pascolo during his PhD work at the University of Tuebingen. His scientific background includes working with Professor Guenther Jung and Professor Hans-Georg Rammensee, renowned scientists in organic chemistry and immunology, respectively. During his one year stay in India he also carried out field studies on leprosy and HIV in collaboration with the World Health Organisation (WHO) at Madurai Kamaraj University. Ingmar Hoerr received his PhD in biology from Tuebingen University, and an MBA from Danube University in Krems, Austria.

Jeffrey Cohen, Director, Healthcare Research, Ladenburg Thalmann & Co.

Jeffrey Cohen

Jeffrey Cohen has over 20 years of professional experience involved in the worldwide financial markets including such companies as Cantor Fitzgerald, the American Stock Exchange (NYSE Euronext), Sanwa Bank and Ladenburg Thalmann. For the past 13 years, Mr. Cohen has been actively involved in direct research, analysis and marketing pertaining to the large and growing $2.7 trillion US healthcare sector, including detailed fundamental and financial analysis specific to the development, marketing, delivery and commercialization of medical technologies, therapeutics, and various other healthcare solutions. During the past seven (7) years, Mr. Cohen has developed, published and presented detailed fundamental analytical reports and financial models for more than 34 publicly traded and privately held medical technology, healthcare service and biotechnology companies with over $14 billion in aggregate market capitalization. Mr. Cohen is an engineer by early training and education (BSE University of Pennsylvania), including several years of work experience planning, designing and implementation of complex fixed-rail automated transportation systems and also holds an MBA and various FINRA licenses.

Jeremy P. Goldberg, Advisor, Torreya Partners

Jeremy P. Goldberg

Jeremy P. Goldberg is a skilled business development executive with over 25 years of experience, mainly focused on investing and business development in the pharmaceutical and healthcare industries. In addition to his work as Advisor at Torreya, he is an advisor to several funds focused on private equity and life sciences investments in the venture and royalty areas. He was a founding partner of ProQuest Investments in 1998, the first cancer-focused venture capital fund, where he and his partners raised over $250 million in Funds I and II to acquire positions in biotechnology, specialty pharmaceutical and medical device companies. Jeremy joined Endo Pharmaceuticals in 2003 as Managing Director, Corporate Development and was responsible for its overall corporate development activities, including structuring, negotiating and closing transactions. Jeremy’s transaction experience includes over 12 product licenses and multi-product license or acquisitions with U.S. and European companies announced while at Endo Pharmaceuticals. Prior operating experience includes roles as founding CEO or founder of three biotechnology companies that were acquired or taken public, including Versicor (Vicuron), a Sepracor spin-out later acquired by Pfizer, and operating roles at SmithKline and Becton Dickinson. He serves on the Dana Farber Cancer Institute Lank Center Visiting Committee and an NIH-Oxford affiliated board. Jeremy received his A.B. from Harvard College and M.B.A from Harvard Business School.

John Gustofson, Director, Business Development, AstraZeneca

John Gustofson

John Gustofson is a Director of Strategic Partnering and Business Development at AstraZeneca. In his current position, John is responsible for identifying, evaluating and negotiating early preclinical to late stage clinical opportunities with a focus on Oncology. John has 19+ years professional experience with early stage biotechnology and pharmaceutical industries. In addition, John spent approximately 4 years in strategy consulting to the life sciences industry. Prior to joining AstraZeneca John held business and market development positions at Altus Pharmaceuticals and Therion Biologics.

John Lambert, EVP & CSO, ImmunoGen

John Lambert

Dr John Lambert is Executive Vice President and Chief Scientific Officer at ImmunoGen, Inc., a biotechnology company with headquarters inWaltham, Massachusetts.

Dr Lambert received a BA in Natural Sciences in 1972 from the University of Cambridge, England, and received a Ph.D. degree in Biochemistry in 1976, also from the University of Cambridge, for his research on the structure of multimeric glycolytic enzymes under the supervision of Professor Richard N. Perham.

He did his postdoctoral training working in the laboratory of Dr Robert R. Traut in the Department of Biological Chemistry, School of Medicine, at the University of California at Davis, where he worked on the structure of ribosomes (1976 – 1980), and with Dr John R. Coggins in the Department of Biochemistry at the University of Glasgow in Scotland (1980 – 1982), where he worked on the arom multienzyme complex.

In 1982, Dr. Lambert joined the Sidney Farber Cancer Institute (later renamed Dana-Farber Cancer Institute), Harvard Medical School, as an Assistant Professor of Pathology, to work with Dr Walter A Blättler on the research program that was funded by ImmunoGen, Inc., to develop anti-cancer therapeutics based on the concept of utilizing monoclonal antibodies to deliver cytotoxic payloads (ADCs) to kill the targeted cancer cells.

In 1987, the ADC research program moved to independent laboratories established by ImmunoGen in Cambridge, Massachusetts, where Dr Lambert was appointed Senior Scientist. In 1990, Dr Lambert became Director of Biochemistry, and in 1992 was appointed Senior Director of Research. He joined the Senior Management team of the Company as a Vice President in 1994, and served in a variety of roles until becoming EVP and Chief Scientific Officer in 2009. Dr Lambert is the author/coauthor of over 100 scientific articles.

Jonathan Burgin, CEO, BioCancell Ltd

Jonathan Burgin

Jonathan Burgin has served as Chief Executive Officer of BioCancell since June 2012, and was previously Chief Financial Officer of the Company from June 2011. Mr. Burgin has been Chief Financial Officer of Radcom, Ltd. (NASDAQ: RDCM), a service assurance provider, since 2006, and was CFO of XTL Biopharmaceuticals (TASE: XTL, Pink Sheets: XTLBY), a drug development company, from 1999 to 2006, where he took an active part in the process of listing its shares on the NASDAQ, London Stock Exchange, and TASE and in raising $113 million in four financing rounds. Between 1997 and 1999, he was CFO of YLR Capital Markets, a publicly-traded Israeli investment bank, and rose to become a Senior Manager at Kesselman & Kesselman, the Israeli member of PricewaterhouseCoopers International, Ltd., between 1984 and 1997. Mr. Burgin earned an M.B.A. and a B.A. in Accounting and Economics from Tel-Aviv University and is certified in Israel as a CPA.

Jonathan Patcher, VP, Head of Research, Verastem Inc.

Jonathan Patcher

Jonathan Patcher brings over 20 years of experience in leading discovery of small molecule and monoclonal antibody therapeutics for treatment of cancer. He was previously Head of Cancer Biology at OSI Pharmaceuticals where his team was responsible for development of models of tumor cell EMT (epithelial-mesenchymal transition) and discovery of drugs disrupting this process. At OSI he advanced five small molecules into development for treatment of cancer, including OSI-906 – a selective IGF-1R/ insulin receptor kinase inhibitor currently in phase III clinical trials and OSI-027 – a selective mTOR kinase inhibitor. Prior to OSI, Dr. Pachter held positions of increasing responsibility at Schering-Plough where he progressed three agents into development including the monoclonal antibody robatumumab which advanced to phase II clinical evaluation in cancer patients. Dr. Pachter also made key contributions to the regulatory approval of temozolomide for treatment of glioblastoma. He is an author of over 40 peer-reviewed publications and inventor on numerous patents. Dr. Pachter did his postdoctoral work in Pharmacology at Yale University School of Medicine and he holds a Ph.D. from Baylor College of Medicine.

Kevin Krenitsky, Chief Commercial Officer & SVP International Strategy,, Foundation Medicine

Kevin Krenitsky

Dr Krenitsky joined Foundation Medicine as the Chief Operating Officer in June 2011, bringing 15 years of experience in building and managing global diagnostic and biotechnology operations to the company. He joins Foundation Medicine from Enzo Clinical Labs where he served as president. In this role, he instituted a comprehensive operational plan that resulted in re-accreditation by the College of American Pathologists and led the introduction of numerous U.S. FDA-approved esoteric tests as well as several new laboratory developed test rollouts, all of which led to significant revenue growth during his tenure.

Prior to Enzo Clinical Labs, he was chief executive officer at BioServe Biotechnologies, a global biotechnology company specializing in processing genetic diagnostic tests, and before that, he served as chief executive officer at Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. Before joining Parkway Clinical Laboratories, Dr. Krenitsky held multiple senior level positions within Genomics Collaborative, Inc. (a SeraCare Life Sciences Company), a full-scale clinical and genomics research company.

Dr. Krenitsky received a BS in business management from the University of Scranton and an MD from Jefferson Medical College.

Laurent Choppe, Managing Partner, Life Sciences, Cukieman & Co.

Laurent Choppe

Laurent Choppe is leading CLS since 2008 and brings an extensive international life science experience in managing multifunctional teams and setting up new businesses in pharmaceuticals, biotechnology, nutraceuticals, animal health and direct-to-consumer markets. After a veterinary practice and a new venture management experience, he spent 10 years in Schering-Plough in various marketing and general management positions in France, Israel and Canada. He then served as international General Manager of BELLUS Health (ex-Neurochem NASDAQ & TSE), a Canadian biopharmaceutical company mainly involved in orphan drugs and Alzheimer’s disease.

Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d'Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD in Fontainebleau (France). He is married, father of 3 and lives in Lausanne (Switzerland).

Leigh Zawel, Executive Director & Oncology Site Lead, Merck Research Laboratories

Leigh Zawel

Dr Leigh Zawel joined Merck in 2010, and is the Oncology Site Lead at Merck Research Laboratories (MRL) Boston. In this role, he is responsible for the drug discovery efforts within the department which are focused on the identification of development candidates for programs in the oncology franchise. Dr. Zawel comes to Merck from Sanofi-Aventis where he was the Director of Cancer Biology. Prior to that he spent 11 years at Novartis Institutes for Biomedical Research/Oncology, where he was the Group Leader for identifying and validating oncology drug targets. Dr. Zawel has a Ph.D. in Biochemistry, was a Postdoctoral Fellow in the laboratories of Drs. Bert Vogelstein and Ken Kinzler at Johns Hopkins University, his M.S. in Bacteriology from the University of Wisconsin, and his B.S. in Biology from Rutgers University. Dr. Zawel has published over 25 scientific publications, and is an author on 45 patents covering chemical matter, drug combinations, biomarker utility and gene function in areas of apoptosis, inflammation and TGFB signaling.

Lorenza Castellón, Health & Biotech Equity Analyst, Equity Development Ltd

Lorenza Castellon

Lorenza Castellón is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international investment organisations. Equity Development brings together investors and companies by means of writing and distributing detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative 400 years of experience. Please visit www.equitydevelopment.co.uk for more details and examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector having worked for leading international investment organisations.

Louis DeGennaro, Executive Vice President, Chief Mission Officer,
Leukemia and Lymphoma Society

Louis DeGennaro

As Chief Mission Officer, Dr DeGennaro's current responsibilities include oversight of all LLS mission functions including Public Policy, Patient Services and Research with the goal of effectively deploying resources in pursuit of the LLS mission to cure leukemia, lymphoma and myeloma and improve the quality of life for patients and their families. The Society’s mission budget exceeds $150 million annually.

Dr. DeGennaro has more than 25 years of research, drug development and executive management experience in academic and private sector settings. He received his Ph.D. in biochemistry from the University of California at San Francisco and did his post-doctoral research at the Yale University School of Medicine. His previous academic appointments include research group leader, Max Planck Institute in Munich, Germany, where his laboratory was among the first to clone genes expressed exclusively in the nervous system; and associate professor of neurology and cell biology, University of Massachusetts Medical School. Dr. DeGennaro's private sector positions include: senior director of molecular genetics at Wyeth Pharmaceuticals, Princeton, NJ, where his department contributed to the development of pantoprazole (Protonix®) to treat acid reflux disease, Effexor (Venlafaxine®) for anxiety and depression and Mylotarg® for leukemia; executive vice president for research and development, SynX Pharma, Inc. in Toronto, Canada, where he was responsible for the development of a point-of-care diagnostic test for congestive heart failure; and research manager at Streck, Inc., Omaha, NE where he helped develop a FDA-cleared diagnostic test for AIDS/HIV.

Dr. DeGennaro has been appointed by Kathleen Sebelius, U.S. Secretary of Health and Human Services, to serve as a member of the newly created National Center for Advancing Translational Sciences Advisory Council, and the Cures Acceleration Network Review Board at the National Institutes of Health (NIH) and he serves on the Board of BioTheryX, Inc., an early-stage biotechnology company.

Louise Perkins, Chief Science Officer, Melanoma Research Alliance

Louise Perkins

Dr Perkins was most recently the Chief Scientific Officer at the Multiple Myeloma Research Foundation (MMRF) where she was responsible for the development and execution of the MMRF's scientific strategy to accelerate development of the next treatments for patients with myeloma, leading to a cure. Her interests center on translational research including target identification, drug discovery and advancement of novel therapeutic approaches. She served as CSO at the MMRF for five years following a research career of 16 years at two major pharmaceutical companies.

While at the MMRF, Dr. Perkins led the continued expansion of its venture philanthropy investments including its Biotech Investment Award and Clinical Fund programs. In addition, she was responsible for the expansion of the MMRF’s Genomics Initiative which sequenced the first myeloma tumor genome in 2009 and has comprehensively analyzed 250 myeloma patient samples with an array of genomic technologies including next-gen sequencing. More recently, Dr. Perkins led the development of the genomics and data sharing strategy underpinning the MMRF’s 1,000 patient longitudinal study, CoMMpasssm, which aims to develop new targets and biomarkers through deep clinical and molecular data capture and analysis.

Prior to joining the MMRF, Dr. Perkins was Director of Cancer Research at Bayer Pharmaceuticals in West Haven, CT, where she contributed to advancing novel targeted therapies toward clinical study, including Nexavar® and other innovative signal transduction inhibitors. While at Bayer, she also served as the Director of Research Licensing and was responsible for oncology licensing activities in support of cancer research programs. Prior to joining Bayer, she led a cancer research group at the Schering-Plough Research Institute in Kenilworth, NJ. In this role, she participated in several early-stage research programs including novel target-finding research using human genomics data.

Dr. Perkins graduated from the University of Michigan with a PhD and MS in Biological Chemistry and conducted postdoctoral studies at Princeton University in the Department of Molecular Biology. She earned her BS in Zoology from the University of North Carolina at Chapel Hill.

Mara Goldstein, Senior Analyst, Cantor Fitzgerald

Mara Goldstein

Mara Goldstein is a managing director and senior analyst covering the biotechnology sector with Cantor Fitzgerald. Ms.Goldstein’s career in equity research spans a broad continuum of life sciences subsectors, including biotechnology, major pharmaceuticals, drug delivery and specialty pharmaceuticals. Prior to joining Cantor Fitzgerald, Ms. Goldstein was most recently with Thomson Reuters, where she served as director of research Reuters Insight, an independent research services business. Ms. Goldstein was initially responsible for the firm's healthcare research practice, and later assumed responsibility for all research activities and sectors. Prior to that, Ms. Goldstein was an executive director and senior pharmaceutical analyst at CIBC World Markets, and she also worked at Alex Brown & Sons (now Deutsche Bank) and CS First Boston (now CSFB). Ms. Goldstein has been quoted in publications such as The Wall Street Journal, New York Times and Newsweek, and has appeared on financial television news programs such as CNBC, Bloomberg TV and ABC World News. She holds a bachelor's degree in economics from Purdue University.

Margaret Anderson, Executive Director, FasterCures

Margaret Anderson

Margaret Anderson is the executive director of FasterCures/The Center for Accelerating Medical Solutions, a Milken Institute center that works to speed up the timeline for new medicines to go from discovery to patients. She is a founding board member and past-president of the Alliance for a Stronger FDA, co-chairs the eHealth Initiative's Council on Data and Research, and is a member of the National Center for Advancing Translational Sciences Advisory Council, the Cures Acceleration Network Review Board, the National Health Council Board of Directors, United for Medical Research Steering Committee, and the Institute of Medicine's Forum on Drug Discovery, Development and Translation. Previously, Anderson was the deputy director and a team leader in the Center on AIDS & Community Health at the Academy for Educational Development, where she led public health projects; program director at the Society for Women’s Health Research; health science analyst at the American Public Health Association, where she managed a programmatic portfolio on HIV/AIDS and other sexually transmitted diseases, infectious diseases, women’s health, and public health infrastructure issues; and analyst and project director at the Congressional Office of Technology Assessment in the Biological Applications Program, where she studied societal and business implications of genetic testing. Anderson holds a bachelor's degree from the University of Maryland and a master's degree in science, technology, and public policy from George Washington University.

Matthew Callahan, President and CEO, Churchill Pharmaceuticals

Matthew Callahan

Matthew Callahan is the founding CEO of Churchill Pharmaceuticals and is leading the commercialization of the Company’s oral oncology drugs. Mr Callahan developed the concept for Churchill and has positioned the company to rapidly progress its four pipeline products through clinical trials to approval.

Churchill is focused on applying technology to address the significant variability, poor bioavailability and serious side effects of many marketed oral oncology drugs. In some cases, the maximum amount of drug (Cmax) absorbed by patients can vary by 17x and the exposure (AUC) can vary by 10x, depending on the effect of food and patient physiology. Because this sometimes means that patients can absorb little or no drug after taking the dose, the efficacy of these drugs is often retarded. Alternatively, due to the variability of these drugs, patients can receive high or toxic doses which can be related to side effects and can result in treatment interruption.

Churchill is a licensee of the SoluMatrix™ technology platform from iCeutica Inc. This proprietary platform allows for drug particles to be reduced in size down to the sub-micron range, thereby significantly increasing their dissolution performance and improving their bioavailability. SoluMatrix™ has been successfully utilized in a number of products in the pain and inflammation area which have completed Phase 3 trials and the first NDA incorporating the technology has been filed.

Churchill has selected four marketed oral oncology drugs for reformulation using the SoluMatrix™ technology and the first of these is planned to enter clinical development in Q4 2013. The pathway for development of these improved versions of the innovator drugs is relatively efficient, as Churchill intends to rely on a portion of the data for each drug which is already the subject of FDA approval.

Mr Callahan was also the founding CEO of iCeutica Inc and has more than 18 years legal, commercial and IP experience. He remains a partner of an Australian venture capital fund and is also currently a director of cell therapies company Orthocell and carbohydrate drug company Glycan Biosciences. He resides in Philadelphia with his wife and three children.

Matthias Jaffe, CFO, Constellation Pharmaceuticals

Matthias Jaffe

Matthias Jaffe joined Constellation in April 2012 bringing over 12 years of experience in corporate finance and strategic management to his role. Previously, he held senior finance and business development positions in a number of private, venture-backed companies in the life science and cleantech space, including Zafgen, Seventh Sense Biosystems, Pervasis Therapeutics and Alantos Pharmaceuticals, which was acquired by Amgen in 2007. Prior to Alantos, Mr. Jaffe was a principal at Earlybird Venture Capital (Munich, Germany), where he supported new investments activities and existing portfolio companies. He also worked at the Boston Consulting Group, where he was a member of the pharmaceutical practice group, assisting Fortune 500 companies with strategic management issues. Mr. Jaffe holds a M.S. in molecular biology from the Massachusetts Institute of Technology, an MBA from INSEAD (Fontainebleau, France).

Michael G. King, Jr, Managing Director and Senior Biotechnology Analyst, JMP Securities LLC

Michael G. King, Jr

Prior to joining JMP,Mike King was a Managing Director at Dawson James Securities, where he served as Director of Research and as a senior biotechnology analyst. He was previously a Managing Director and senior research analyst at Rodman & Renshaw, a Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology, and a Managing Director and senior equity analyst at Wedbush Securities. Beforehand, Mike served as a Managing Director and senior biotechnology analyst both at Merriman Curhan Ford and at Rodman & Renshaw, where, in his initial tenure with the company, he was also the Director of Research. Additionally, Mike has held senior equity research positions at Banc of America Securities, Robertson Stephens, Vector Securities and Dillon Read & Co., covering a wide range of market capitalizations and therapeutic categories. He began his career as a biotechnology specialist in the private client sales divisions of Alex. Brown & Co., Hambrecht & Quist and Kidder, Peabody & Co. In 2013, Mike ranked first among all stock pickers in the Pharmaceuticals category in the annual “Best on the Street” analyst survey conducted by The Wall Street Journal.

Mike holds a BA in finance from The Bernard M. Baruch College of the City University of New York.

Neil Exter, Partner, Third Rock Ventures and CBO, Blueprint Medicines

Neil Exter

Neil Exter joined Third Rock Ventures in 2007 and plays an integral role in the overall formation, development and business strategy of our portfolio companies. Additionally, he supports the business development efforts within the portfolio companies. He also assumes active leadership roles in our portfolio companies, functioning as interim COO/CBO through the first 12-18 months post launch.

Neil has over 20 years of business development and strategic experience, facilitating the successful development and implementation of operations and collaborations across the spectrum of newly emerging and established biotech companies.

Prior to joining Third Rock Ventures, Neil was CBO of Alantos Pharmaceuticals, leading the sale of the company to Amgen. Previously, Neil served as VP for Millennium Pharmaceuticals, directing in-licensing and M&A. Earlier in his career, Neil held various executive management roles within the high technology industry, including tenures at Hewlett Packard and Wang Laboratories.

Nicholas Dracopoli, Vice President and Head of Oncology, Janssen Research & Development

Nicholas Dracopoli

Dr Nicholas Dracopoli is Vice President/Head of Oncology Biomarkers at Janssen R&D, LLC of Johnson & Johnson. In this role he is responsible for biomarker discovery, development and application for oncology products. Previously, he was Vice President of Clinical Discovery Technologies at Bristol-Myers Squibb, and prior to that spent five years in the biotechnology industry at Sequana Therapeutics. Dr Dracopoli obtained his B.Sc. and Ph.D. degrees from the University of London, and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center and the Massachusetts Institute of Technology (MIT). Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center and as a Section Chief at the National Center for Human Genome Research at the NIH before moving to the biotechnology industry. Dr Dracopoli has authored >70 scientific publications, and has extensive experience in the fields of genomics, molecular biology and cancer research.

Paul Higham, CEO, immatics biotechnologies GmbH

Paul Higham

Paul Higham was appointed as CEO of immatics in August 2008. Previously, he served as Director Commercial Development at Ark Therapeutics Group plc where he was responsible for commercial strategy and all business development activities. In addition, he was in charge of establishing the operations and gene-based medicine production facilities of Ark Therapeutics in Finland.

Prior to joining Ark Therapeutics in 2001, Paul Higham worked as International Commercial Vice President for GI, Metabolic and Pain at GlaxoWellcome plc from 1996 to 2001, where he was responsible for all aspects of business development, strategic marketing, sales and finance. From 1985 to 1996, after completing his studies in Applied Biology, he held various sales and marketing positions of increasing responsibility with Bayer AG and eventually became General Manager of Bayer Pharmaceuticals for Sweden and Denmark.

Paul Juniewicz , North American Head of Oncology Business Opportunities, Sanofi

Paul Juniewicz

Paul Juniewicz is currently the North American Head of Oncology Business Opportunities (OBO) within the Strategic Portfolio and Management Group of the Oncology Division for Sanofi. Within this group, Paul and his Team are responsible for scouting and evaluating external oncology opportunities and possible research collaborations and making recommendations on these external opportunities/ research collaborations to the Oncology Review Board (ORB) and other Senior Management Committees, in particular the External Working Group (EWG). The OBO Team works closely with all groups within the Oncology Division and in close collaboration with Business Development and the Strategy, External Innovation & Science Policy Department.

Prior to this current role, Paul was most recently Vice-President within the External Innovation Department of sanofi-aventis, Research + Development responsible for scouting and evaluating early research opportunities across all therapeutic areas.

Previous to that role was Vice-President Oncology Projects, Project Direction responsible for the development and registration of oncology projects including Eloxatin (oxaliplatin) and Elitek (Rasburicase).

Paul received his BS from Rutgers University, MS and PhD from North Carolina State University and conducted post-doctoral training at Johns Hopkins University. Paul joined Sterling Drug in 1987 as a research scientist and transitioned to Sanofi, Sanofi-Synthelabo, sanofi-aventis and most recently Sanofi / Genzyme.

Patrick Fortune, General Manager, Cleveland Clinic Innovations

Patrick Fortune

Patrick Fortune PhD, MBA, director, technology development and selection, is Senior General Manager of Cleveland Clinic Innovations and served as a member of CCI’s Innovation Advisory Board for 7 years prior to joining CCI. Dr. Fortune was a partner at Boston Millennia Partners for more than decade, with responsibility for investing in early stage healthcare companies. Dr. Fortune senior leadership experience in the healthcare, life sciences and information technology sectors and has nurtured start-up activities from idea to prototype to standalone business throughout his career and has taken more than 30 companies through to a monetization. He has been a senior executive at multiple Fortune 500 companies, including president and COO of New Era of Networks; corporate VP at Monsanto; VP at Bristol Myers Squibb; and group president, as well VP of R&D, at Baxter International. Dr. Fortune currently serves on the boards of directors of Parexel International Corp, a global $2.5-billion contract research organization (NASDAQ, PRXL), and several private, life sciences companies. He holds a B.A. and a PhD in physical chemistry from the University of Wisconsin, and an MBA from Northwestern University.

Petter Björquist, Senior Principal Scientist and Department Head, Cellectis

Petter Björquist

Patrick Fortune Petter Björquist, Ph.D., Senior Principal Scientist and Department Head, at Cellectis Stem Cells, responsible for the areas stem cell-derived hepatocytes and beta-cells.

PB has about ten years of experience from AstraZeneca R&D, Sweden, where he was previously active in a project management team in the therapeutic area Cardiovascular Diseases. PB is the author of more than 40 scientific articles, and is today heading a team of about 15 scientists.

He is also supervising both PhD-students and postdocs, and is coordinating the major collaboration between Novo Nordisk and Cellectis on using regenerative medicine for treatment of diabetes.

Philip Gotwals, Executive Director, Oncology Research Collaborations,
Novartis Institute for Biomedical Research

Philip Gotwals

Philip Gotwals is currently Executive Director, Oncology Research Collaborations, responsible for overseeing global strategic research alliances in the Oncology Disease Area at Novartis Institutes of BioMedical Research. Dr. Gotwals has over 15 years of experience in the biotechnology and pharmaceutical industries managing internal and collaborative product development programs from discovery to NDA filing, and participating in the licensing of product candidates. Phil is the former Vice President, Project Management at Altus Pharmaceuticals responsible for all product development project management activities. Prior to his engagement at Altus, Phil was Senior Director, Program and Alliance Management at Biogen Idec where he oversaw management of internal and allied early product development teams in the autoimmune, neurology and oncology therapeutic areas. Dr. Gotwals holds a PhD in Genetics and Molecular Biology from the University of California at Berkeley, and finished post-doctoral research at the Massachusetts Institute of Technology.

Punit Dhillon, Co-Founder, Director and CEO, OncoSec Medical Incorporated

Punit Dhillon

Punit Dhillon's was formerly Vice President of Finance and Operations at Inovio Pharmaceuticals, Inc., until March 2011. In his corporate finance role, Mr. Dhillon was pivotal to the company raising over $125 million through multiple financings and several licensing deals including early stage deals with Merck and Wyeth. He was also instrumental to the successful in-licensing of key intellectual property and a number of corporate transactions, including the acquisition and consolidation of Inovio AS, a Norwegian DNA delivery company, and led the merger with VGX Pharmaceuticals, which solidified Inovio’s position in the DNA vaccine industry. As head of operations, he successfully completed the integration of the VGX-Inovio merger including cost-cutting of over 30% through the synergy assessment of both companies, consolidation of four operating locations in to two bi-coastal offices, corporate rebranding and management of existing shareholders from both companies. Mr. Dhillon has been a consultant and board member for several early stage life science companies. Prior to joining Inovio, Mr. Dhillon worked for a corporate finance law firm as a law clerk. Previous to 2003, he worked with MDS Capital Corp. (now Lumira Capital Corp.) as an intern analyst.

Mr. Dhillon is a mentor to the TiE Young Entrepreneurs (TYE) Program where he recently led his team of students to win the 2012 global business plan competition in Atlanta. He is an active member in his community and advocate for cancer research and advancing the availability of healthcare.

In 2012, Mr. Dhillon helped raise over $30,000 to support the British Columbia Cancer Foundation and the British Columbia Children’s Hospital through charitable contributions. He is also the co-founder of Inbalance Network Inc., a wellness organization focused on promoting an active lifestyle and grassroots community involvement, including scholarships that support students pursuing post-secondary education. Mr. Dhillon has a Bachelor of Arts with honors in Political Science and a minor in Business Administration from Simon Fraser University. He resides in San Diego, California with his wife and two daughters, and enjoys being active through competitive running, swimming and biking.

Rafael Amado, SVP, Head of Oncology R&D, GlaxoSmithKline

Rafael Amado

Rafael Amado is Senior Vice President, Oncology R&D at GlaxoSmithKline. He is accountable for integrating oncology R&D efforts from drug target identification through late-stage development and registration globally.

Rafael joined GSK in 2008 as Vice President, Medicine Development Leader. In that capacity he was responsible for developing and executing the asset’s development strategy globally. He served in positions of increasing responsibility as Vice President, Oncology Solid Tumors and Senior Vice President, Oncology Development.

Prior to joining GSK, Rafael was Executive Director in the Therapeutic Oncology Area at Amgen where he was responsible for development activities of several assets. An area of his interest is biological characterization of tumors for patient selection, which he successfully applied to targeted drug development. Rafael trained as a Hematologist/Oncologist at the University of California, Los Angeles, where he remained as faculty until joining Amgen in 2003.

Rafael has led the development of numerous small molecules and biologic products through initial registration and label extensions. A native of Spain, he holds an M.D. from the University of Seville School of Medicine. He performed his residency in Internal Medicine at Michael Reese Hospital, a University of Chicago Affiliated Hospital, and his fellowship in Hematology/Oncology at the University of California, Los Angeles. He has published extensively in his field, and is a member of the American College of Physicians, the American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research.

Prof. Ronit Satchi-Fainaro, Tel Aviv University

Prof. Ronit Satchi-Fainaro

Prof. Ronit Satchi-Fainaro (Ph.D.) is Head of the Cancer Angiogenesis & Nanomedicine Lab; Associate Professor, Department of Physiology & Pharmacology, Sackler School of Medicine. Prof. Satchi-Fainaro received her Bachelor of Pharmacy from the Hebrew University, Israel (1995) and her Ph.D. from the University of London, UK (1999). She then spent two years as postdoctoral fellow at Harvard University and Children’s Hospital Boston working with Judah Folkman on novel angiogenesis-targeted nanomedicines. In 2003, she was appointed Instructor at Boston Children’s Hospital and Harvard Medical School. She joined Tel Aviv University in 2006.

She is a leader in the field of nanomedicine and angiogenesis (cancer and vascular biology). She serves as advisor to several Israeli and International biotech companies, is President of the Israeli Society for Controlled Release, and is on the editorial boards of several biological and chemical journals. She has published more than 55 papers, 12 book chapters, edited 2 books, is named inventor on 20 patents, and was awarded numerous prestigious grants and prizes, among them Fulbright, Rothschild, Wingate, Alon, Young Investigator Award of the European Association for Cancer Research, 50 most influential women in Israel (Globes, TheMarker, Forbes) and Juludan.

She has major expertise in tumor biology, tumor dormancy, angiogenesis, molecular imaging, non-invasive intravital imaging of animal models, theranostics and nanomedicines for personalized medicine. Throughout, she has maintained an interest in understanding the biological rationale for the design of nanomedicines suitable for transfer into clinical testing. Her multi-disciplinary research laboratory focuses on basic research leading to the design of highly-selective targeting molecules integrating biology, chemistry, protein engineering, molecular imaging, computational approaches, material sciences and nanotechnology to selectively guide drugs into pathological sites.

Seth Yakatan, Co-Founder, Katan Associates

Seth Yakatan

Seth Yakatan brings more than 20 years of experience as a corporate finance professional, actively supporting small cap and major companies in achieving corporate, financing and asset monetization objectives through the successful structuring and management of strategic transactions and investments totaling more than several billion dollars in value.

Over the past twelve years as a co-founder of Katan Associates (KAI), Seth has successfully structured and managed strategic alliances and deals, based on his insight and expertise in the US and Global Life Science sector, including numerous buy- and sell-side M&A transactions.

Completed Life Science transactions at KAI include:
• Twelve buy and sell-side M&A engagements, generating aggregate transaction value in excess of $345 million.
• Numerous early-stage pharmaceutical partnering assignments with aggregate value generated for clients of more than $875 million.
• Facilitation of several royalty monetization transactions, with aggregate realized value in excess of $125 million.

Prior to founding Katan Associates in 2001, Seth worked in merchant banking at the Union Bank of California, N.A., in the Specialized Lending Media and Telecommunications Group. During his six years there, he completed the placement of subordinated debt and private equity investments, exceeding $3 billion in transaction value.

Seth began his career as a venture capital analyst with Ventana Growth Funds and Sureste Venture Management, where he gained significant experience in creating successful venture-backed life science companies.

Seth is a recognized as an expert in the valuation of life sciences companies, stemming from industry experience and academia. He has authored several publications and lectured and guest lectured at corporate workshop and universities on valuation theory and real-world practice and case studies, and consulted to several state and provincial governments worldwide on commercialization and capital access initiatives.

Seth has also served as a speaker and faculty member at industry conferences including the Annual BIO International Convention Executive Workshop Series. Seth serves as an advisor to Boston Communications, a communications consulting firm that supports business leaders in addressing their greatest communications challenges, and to The Brookwood Group, a specialized real estate and restaurant consulting firm.

Seth holds an MBA in Finance from the University of California, Irvine and a BA in History and Public Affairs from the University of Denver.

Seth enjoys being a Dad to his two children, participating in triathlons and cycling.

Sheikh Usman Iqbal, Head of Oncology, Global Evidence & Value Development, Medical Affairs, Global R&D, Sanofi

Sheikh Usman Iqbal

Dr Usman Iqbal MD, MPH, MBA is the head of Oncology Global Evidence & Value Development at Sanofi, where he is responsible for developing product value for Sanofi’s oncology/hematology portfolio through strategic development, execution and translation of evidence based research throughout the lifecycle of the products. His health care experience spans clinical medicine, health policy and management, health economic & outcomes research in both academia and biopharmaceutical industry, including Amgen and Boehringer Ingelheim. Dr Iqbal has broad based experience in building value and product differentiation across multiple therapeutic areas including oncology, respiratory, rheumatology, hepatology, and mental health. Prior to working in the industry, Dr Iqbal was at the Boston University Health Outcomes Technology Group as a senior research fellow and served as a research consultant for Veterans Affairs Pharmacy Benefit Management (VA-PBM), the Centers for Medicare & Medicaid Services’ Health Outcomes Survey Initiative (CMS-HOS), the Agency for Healthcare Research and Quality (AHRQ), and the National Committee for Quality Assurance (NCQA). His research experience encompasses outcomes evaluation in large integrated health care systems and databases with a specific focus on comparative effectiveness, disease management, patients’ health related quality of life, and risk-adjustment methodologies. Dr Iqbal received his MD from Allama Iqbal Medical College, Lahore, Pakistan and Master of Public Health and Master of Business Administration from Boston University.

Steve Tregay, CEO, Forma Therapeutics

Steve Tregay

Prior to joining FORMASteve Tregay was a Managing Director for the $200M Novartis Option Fund. He led the fund’s investments in and served on the Board of Directors of FORMA Therapeutics, Adenosine Therapeutics (acquired by Clinical Data: FRX) and Cequent Pharmaceuticals (acquired by Marina Biotech: MRNA). Prior to joining the venture group, he was the Executive Director and Head of Strategic Alliances-Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team who were responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development at Array BioPharma and research. He received his Ph.D. and M.S. in organic chemistry from Harvard University and a B.S. from Davidson College.

Steven Quay, CEO, Atossa Genetics

Steven Quay

Steven Quay's MD, PhD, FCAP, is a board-certified anatomic pathologist, with training at The Massachusetts General Hospital, Harvard Medical School, and the Chemistry department, Massachusetts Institute of Technology, and is a former faculty member of the Department of Pathology, Stanford University School of Medicine. Dr. Quay is a member of the American Society of Investigative Pathology, the Association of Molecular Pathology, the Society for Laboratory Automation and Screening, and the Association of Pathology Informatics.

Steven W. Young, President, Addario Lung Cancer Medical Institute

Steven Young

Steven W. Young has served as the president & Chief Operating Officer of the Addario Lung Cancer Medical Institute since 2008. Mr. Young prior position was Executive Director of the Multiple Myeloma Research Consortium, after having directed the launch of a number of for-profit clinical research initiatives models. Earlier still, he served as Administrative Director of the General Clinical Research Center at Mount Sinai School of Medicine and the Pediatric Clinical Research Center at Cornell University College of Medicine, both in New York City.

Stuart Barich, Managing Director, Healthcare Investment Banking, Oppenheimer & Co.

Stuart Barich

Stuart Barich has been with Oppenheimer since September 2005 as a Managing Director focusing on Life Sciences. He has participated in the successful completion of over 150 transactions during his career covering a broad spectrum of equity and mergers and acquisitions. Prior to joining Oppenheimer, he spent five years at Leerink Swann completing numerous transactions for Biotechnology and Specialty Pharmaceutical companies. Prior to joining Leerink, he directed the healthcare banking efforts at Oscar Gruss & Son and Auerbach, and began his career as a Corporate Finance Associate with Paine Webber. Mr. Barich earned a BS in Electrical Engineering from the University of Rochester and an MBA with honors from Columbia Business School.

Tamar Raz, VP Marketing and Strategy, Ramot

Tamar Raz

Tamar Raz PhD., serves as VP Marketing and Strategy, responsible for strategic alliances and marketing activities. Prior to assuming her current position, she was Director of Business Development at Ramot, managing business development activities for life science technologies developed at TAU.

Her Ph.D. and M.Sc. degrees were earned in the field of Embryology & Teratology from Tel Aviv University.

Prior to joining Ramot in 2004, Tamar directed the establishment of Allergene, Ltd., founded as an incubator project in 1998, and served as its CEO until the end of 2003. She established and managed corporate and academic relationships, animal models research, and pre-clinical development operations. She was also responsible for raising funds - yielding a first round investment of venture capital; corporate collaborations; contractual research relationships; and government grants.

Timothy Herpin, VP, Strategic Partnering Business Development Oncology, Science & Trading,
AstraZeneca

Timothy Herpin

Timothy Herpin joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for CNS& Pain and more recently for Oncology & STL. In this role, he leads a team of business development professionals involved in all aspects of deal making for the Oncology franchise. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction execution in multiple disease areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmacopeia. Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University College London and an MBA in Finance from NYU Stern.

Yong S. Chen, Senior Director, Head of Biology, Aileron Therapeutics

Yong Chen

Yong S. Chen has served as our Head of Biology and Translational Research since April 2011 and leads cell and molecular biology, translational pharmacology, DMPK, and in vivo pharmacology. He also served as the program lead and the Alliance Manager for the collaboration with Roche. Yong joined Aileron from MedImmune, Inc. where he was the head of translational pharmacology. As one of the senior members of the Global Oncology Leadership Team and research review committee, Dr. Chang played an instrumental role in formulating strategy and direction for the departments of Oncology and Translational Sciences. He also led multiple research and translational development teams. Prior to MedImmune, he worked with Bayer Pharmaceuticals, where he held positions with increasing responsibilities and contributed to the launch of Nexavar® (sorafenib). Prior to Bayer, Dr. Chang worked at Roche Pharmaceuticals.

Dr. Chang received a B.S. in premedicine and biology and a Ph.D. in physiology from Pennsylvania State University, and was a postdoctoral research fellow at Harvard Medical School/Massachusetts General Hospital.

 
Conference Guide:
Click the cover below to download the full conference guide.
Sachs Conference Guide
Sachs on TwitterFollow us on Twitter @SachsAssociates
To learn more about presenting, exhibition or sponsorship opportunities, please contact Zoe Harris
+ 44 (0)203 463 4890 or by email: Zoe Harris.
  Pharma Licensing
  Groups represented
  on the program
  include:
AstraZeneca GlaxoSmithKline Janssen Research & Development Merck & Co Merck Serono Novartis Novartis Sanofi
 
  Regional Partners:
Mass Bio
Swiss Biotech
 
  Meeting Scheduler
1-2-1 Meeting system
 

 

 
  Sachs Boston Supporting Organisations